Navigation Links
Histogen’s Composition for Oncology Treatments Receives US Patent
Date:10/8/2014

San Diego, CA (PRWEB) October 08, 2014

Histogen Oncology, a company developing innovative cancer therapies based on Histogen’s regenerative medicine technology, today announced that the United States Patent & Trademark Office has issued patent 12/363,479 entitled “Extracellular matrix compositions for the treatment of cancer” to Histogen.

The patent, which is the fifth U.S. patent issued to Histogen, covers the soluble and insoluble compositions of proteins and cofactors that are secreted by multipotent stem cells through Histogen’s technology process for use in the treatment of cancer. The patent claims to support the use of the compositions alone or as a delivery system for traditional chemotherapeutic agents.

Through the recent formation and funding of the Histogen Oncology joint venture, research and development of the unique, naturally secreted compositions is progressing toward a Phase I clinical trial for end stage pancreatic cancer.

“We are pleased about the timely issuance of our U.S. patent for the treatment of cancer,” said Dr. Gail K. Naughton, Histogen CEO and Chairman of the Board. “Our collaborations with top institutions continue to produce mounting evidence supporting the unique mechanism of action of our secreted material in preventing metastasis and reducing tumor load while having no toxic affect on normal cells.”

Histogen’s composition has shown effectiveness in inhibiting over 21 human cancer cell lines both in vitro as well as in animal models. The mechanism of action of the secreted material is through the induction of apoptosis (controlled cell death) primarily in malignant cells, so there is little to no toxicity to normal cells. Histogen Oncology is studying the efficacy of a small molecular weight fraction of the cell secreted composition as a stand alone treatment as well as in combination therapy to evaluate whether effectiveness can be demonstrated with less toxic drug doses.

About Histogen
Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen’s technology focuses on stimulating a patient’s own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit http://www.histogen.com.

Read the full story at http://www.prweb.com/releases/2014/10/prweb12232206.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Histogen’s Method of Generating Multipotent Stem Cells Receives US Patent
2. Histogen’s Composition for Hair Growth Receives US Patent
3. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
4. Bio/Pharmaceutical Contract Manufacturing - Industry Analysis of Dose Manufacturing by the Numbers: Composition, Size, Market Shares, Profitability and Outlook
5. KaloBios Receives Notice of Allowance for Key Composition of Matter Patent Covering KBOO4
6. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
7. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
8. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
9. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
10. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
11. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2019)... ... , ... Cheyenne is a beautiful and strong Quarter Horse and a huge ... Rebel’s Run , which offers riding lessons and trail riding in Afton, Virginia. ... Mimi describes her as her “go to horse.” Thus, you can imagine the ...
(Date:10/3/2019)... ... October 02, 2019 , ... Rapid Novor, Inc., the world's ... it has moved into a new, 5000 sqft, purpose-built, state-of-the-art facility. Now home ... the company's continuous commitment to quality research and service offerings. , ...
(Date:9/24/2019)... ... 24, 2019 , ... Drug resistance has been declared as one of the ... becoming one of the most serious concerns. Hong Kong cannot be spared from the ... (CA-MRSA), or a seven-fold of the figure in 2007 – the year the disease ...
(Date:9/24/2019)... ... September 24, 2019 , ... In the past three years, the ... faculty at South Dakota School of Mines & Technology that expands human ... to surfaces to form a slimy and yet strong layer which is commonly known ...
Breaking Biology Technology:
(Date:10/19/2019)... (PRWEB) , ... October 18, 2019 , ... ... share their research, new ideas, and experience the best their field has to ... relating to life-science projects in industry and research. , Micro- and Nanopositioning Stages ...
(Date:10/17/2019)... ... 2019 , ... LeadingBiotech , an exclusive event series ... NY/NJ CEO conference to be held on November 5, 2019 at ... event offers senior-level industry leaders a unique opportunity to collaborate, build partnerships and ...
(Date:10/10/2019)... SAN DIEGO (PRWEB) , ... October 09, 2019 ... ... their merger-acquisition of Nanosens Innovations, Inc., the creators of CRISPR-Chip™. Cardea first ... announcement of their Early Access Program for the Genome Sensor™. Built with CRISPR-Chip ...
Breaking Biology News(10 mins):